Transient Visual Loss due to Infliximab Administration: A New Adverse Event to Biologic Therapy in Crohn's Disease

A 29-year-old patient diagnosed with Crohn's disease was proposed to start infliximab (IFX) therapy. During the infusion of the first dose, the patient complained of sudden visual impairment. The ophthalmologic evaluation confirmed a best-corrected visual acuity of 8/10 of the left eye (Snellen Chart). Despite its favorable safety profile, IFX is associated with several paradoxical adverse events. Ocular adverse events represent part of this group of complications. We report a case of a not yet reported paradoxical adverse event during the first administration of IFX. The event manifested as a transitory sudden asymmetric loss of visual acuity.